Public Equities Strategy

Our public equities strategy is a long bias, fundamental, bottoms-up equity long/short strategy investing in global healthcare equities across sectors: innovative drugs, devices, diagnostics and data.

The strategy’s investment style is a “best idea” orientation focused on identifying mis-priced risk in clinical, regulatory, intellectual property, manufacturing, commercial, and management.